Renascience (4889.T) Stock Price

Renascience Price

CLOSED
993.00
​
Market closed

Revenue at Renascience has contracted by 0.7% per year over the past 6 years to 68.55 M JPY. For Renascience, the net margin of -439.5% is down versus -246.8% a few years ago.

Renascience stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience business model & stock analysis

Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions.

Frequently asked questions about Renascience

Converted at the current exchange rate, the Renascience share trades at 5.65 EUR (993.00 JPY).

The revenue of Renascience is 68.55 M JPY. This figure is based on current financial data and reflects the company's business performance.

The profit of Renascience is -301.28 M JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Renascience is currently -45.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Renascience stock.

The price-to-sales ratio (P/S) of Renascience is currently 199.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Renascience stock.

The Eulerpool Quality Score for Renascience is 2/10.

The ISIN of Renascience is JP3981100005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Renascience is 4889.T. The ticker symbol is used to trade Renascience shares on the stock exchange.

Fair ValueTerminal
1,052.58 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
22.85 M JPY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
JPY
Initial public offering
Sep 24, 2021
ISIN
JP3981100005
Cusip
J6437J108
Market capitalization
13.16 B JPYLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
—
P/Se
—
EV/EBIT
—
P/B Ratio
3.96
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-9.07 %
Last updated Oct 24, 2026, 1:32 PM

Renascience Peer Group

Renascience FIGI

4889:JP · BBG0125DQD124889:JT · BBG0125DQD214889:JJ · BBG0125DQDC04889:JE · BBG0125DQDG64889:JI · BBG0125DQDH54889:JU · BBG0125DQDJ34889:JW · BBG0125DQDK14889:JV · BBG0193RDSZ2

All fundamentals and in-depth analysis of Renascience

Our stock analysis for Renascience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Renascience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.